- Home
- KMDA vs DCTH Comparison
KMDA vs DCTH Comparison
Compare KMDA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- DCTH
- Stock Information
- Founded
- KMDA 1990
- DCTH 1988
- Country
- KMDA Israel
- DCTH United States
- Employees
- KMDA N/A
- DCTH N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- KMDA Health Care
- DCTH Health Care
- Exchange
- KMDA Nasdaq
- DCTH Nasdaq
- Market Cap
- KMDA 349.6M
- DCTH 398.2M
- IPO Year
- KMDA N/A
- DCTH N/A
- Fundamental
- Price
- KMDA $7.16
- DCTH $14.31
- Analyst Decision
- KMDA Strong Buy
- DCTH Strong Buy
- Analyst Count
- KMDA 2
- DCTH 4
- Target Price
- KMDA $14.50
- DCTH $22.25
- AVG Volume (30 Days)
- KMDA 142.0K
- DCTH 411.6K
- Earning Date
- KMDA 03-05-2025
- DCTH 11-08-2024
- Dividend Yield
- KMDA N/A
- DCTH N/A
- EPS Growth
- KMDA 124.29
- DCTH N/A
- EPS
- KMDA 0.27
- DCTH N/A
- Revenue
- KMDA $158,380,000.00
- DCTH $22,644,000.00
- Revenue This Year
- KMDA $15.81
- DCTH $1,605.13
- Revenue Next Year
- KMDA $5.79
- DCTH $111.67
- P/E Ratio
- KMDA $26.36
- DCTH N/A
- Revenue Growth
- KMDA 4.52
- DCTH 945.91
- 52 Week Low
- KMDA $4.74
- DCTH $3.70
- 52 Week High
- KMDA $8.00
- DCTH $14.47
- Technical
- Relative Strength Index (RSI)
- KMDA 70.04
- DCTH 70.27
- Support Level
- KMDA $7.00
- DCTH $12.14
- Resistance Level
- KMDA $8.00
- DCTH $12.98
- Average True Range (ATR)
- KMDA 0.31
- DCTH 0.77
- MACD
- KMDA 0.06
- DCTH 0.16
- Stochastic Oscillator
- KMDA 60.93
- DCTH 95.12
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.